In people without diabetes, taking evolocumab for about two years does not raise the likelihood of developing diabetes, even in those with prediabetes. The data show no meaningful change in diabetes...

Pro

Against

Mechanism

Synthesis from 1 study

How it works

This drug lowers bad cholesterol by helping the liver remove it from the blood, but it doesn't touch how the body handles sugar or how the pancreas makes insulin. That's why blood sugar stays normal and diabetes doesn't develop, even after years of treatment.

Most probable mechanism

In Simple Terms

Lowering bad cholesterol with this drug doesn't change how the body uses insulin or how the pancreas releases it, so blood sugar stays normal and diabetes doesn't develop.

Causal chain

PCSK9 inhibition increases hepatic LDL receptor expression, enhancing clearance of low-density lipoprotein from the bloodstream

Verified by multiple studies

which leads to

Reduced circulating LDL does not alter insulin receptor signaling in skeletal muscle, adipose tissue, or liver

Verified by multiple studies

which leads to

Pancreatic beta-cell glucose sensing and insulin secretion remain unchanged in the presence of sustained LDL reduction

Verified by multiple studies

Evidence from Studies

Supporting (1)

Community contributions welcome

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.

Randomized Controlled Trial

Human

Contradicting (0)

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.

Score: 73

DOI: 10.1016/S2213-8587(17)30313-3

Similar Assertions

In people with prediabetes and heart disease, taking evolocumab for about two years does not increase the risk of developing diabetes, based on measurements of blood sugar levels and diabetes incidence over time.

89%

In people with diabetes, taking the cholesterol-lowering drug evolocumab for about two years does not lead to changes in blood sugar levels compared to a placebo.

85%

In clinical studies, the rate of side effects from evolocumab was similar to that of a placebo, regardless of whether patients had diabetes or not.

85%

In adults with diabetes who do not have advanced artery disease, a drug called evolocumab lowers LDL cholesterol levels from 111 mg/dL to 52 mg/dL after 48 weeks of treatment, even when patients are already taking the highest tolerated dose of statins.

84%

In adults with diabetes who do not have advanced artery disease, a drug called evolocumab lowers LDL cholesterol by about half after 48 weeks of treatment, resulting in significantly lower cholesterol levels compared to a placebo.

82%